This CME program, derived from content presented at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland, will highlight the utilization of immunohistochemistry testing, biomarkers, and targeted therapeutics to optimize outcomes in patients with non-small cell lung cancer (NSCLC). The expert faculty, led by Dr. Solange Peters, will first review the scientific advances for the identification of NSCLC biomarkers, and associated serum, and immunohistochemistry testing. Next, an analysis of the latest clinical trial data for biomarker-driven targeted therapeutics will be discussed. Following, the faculty will assess how to develop treatment strategies that account for the role of CEACAM5 targeted therapeutics to improve outcomes in patients with CEA-positive NSCLC. Upon completion of this activity, learners will gain better insight into how to treat their patients with non-small cell lung cancer utilizing immunohistochemistry testing, biomarkers, and targeted therapeutics.
Oncologists, pathologists, advanced practice providers, and other healthcare professionals who care for patients with non-small cell lung cancer
I. Welcome & Introductions – Solange Peters, MD, PhD
II. Identification of NSCLC Biomarkers and Associated Serum and Immunohistochemistry Testing – Hossein Borghaei, DO, MS
III. Clinical Trial Review for Biomarker-Driven Targeted Therapeutics – Natasha Leighl, MD
IV. The Role of CEACAM5-Targeted Therapeutics to Improve Outcomes in Patients with CEA-Positive NSCLC – David Planchard, MD, PhD
- Review the scientific advances for the identification of NSCLC biomarkers and associated serum and immunohistochemistry testing
- Analyze the latest clinical trial data for biomarker-driven targeted therapeutics, including CEACAM5 for patients with NSCLC
- Develop treatment strategies that account for the role of CEACAM5 targeted therapeutics to improve outcomes in patients with CEA-positive NSCLC
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Solange Peters, MD, PhD||Consultant/Advisor: AbbVie; AiCME; Amgen; Arcus; AstraZeneca; Bayer; Beigene; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Daiichi Sankyo; Debiopharm; ecancer; Eli Lilly; Elsevier; F-Star; Fishawack ; Foundation Medicine; Genzyme; Gilead; GSK; Illumina; Imedex; IQVIA; Incyte; Ipsen; iTeos; Janssen; Medscape; Medtoday;Merck Sharp and Dohme; Merck Serono; Merrimack; Novartis; Novocure; OncologyEducation ; Pharma Mar; Phosplatin Therapeutics; PER; Peerview; Pfizer; Regeneron; RMEI; Roche/Genentech; RTP; Sanofi; Seattle Genetics; Takeda; Vaccibody
Grants/Research Support: Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; GSK ; Merck Sharp and Dohme ; Roche/Genentech
Speakers Bureau: AiCME; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; ecancer; Eli Lilly; Foundation Medicine; GSK; Illumina; Imedex; Ipsen; Medscape;Merck Sharp and Dohme; Mirati; Novartis; PER; Peerview; Pfizer; Roche/Genentech; RTP; Sanofi; Takeda
|Hossein Borghaei, DO, MS||Consultant/Advisor: Amgen; AstraZeneca; Axiom; Beigene; BioNTech; BMS; Boehringer Ingelheim; Daiichi; Da Volterra; EMD-Serono; Genentech; Genmab; Guardant; iTEO; Janssen; Jazz; Kriya; Lilly; Merck; Mirati; Natera; Novartis; Oncocyte; Pfizer; PharmaMar; Regeneron; Takeda,
Grant/Research Support: BMS/Lilly; Merck/Celgene; Millennium
Stock Options: Nucleai; Sonnetbio; Rgenix
|Natasha Leighl, MD, MMSc||Consultant/Advisor: Bayer; GSK; Puma Biotechnology
Grant/Research Support: Amgen; Array; AstraZeneca; Bayer; BMS; Eli Lilly; EMD Serono; Guardant Health; Inivata; Janssen; MSD; Novartis; Pfizer; Roche; Takeda
|David Planchard, MD, PhD||Consultant/Advisor: Abbvie; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Janssen; Novartis; Pfizer|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
This activity has been supported by an independent educational grant from Sanofi
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].